|Bid||0.00 x 3100|
|Ask||0.00 x 3100|
|Day's range||6.84 - 7.30|
|52-week range||0.25 - 18.77|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 Aug 2021 - 16 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.38|
Noble Capital analyst Robert LeBoyer initiated coverage of the stock with an unhesitant outperform (i.e., buy) recommendation. Like many Ocugen bulls, LeBoyer is most excited about Covaxin. This is the coronavirus vaccine candidate currently being developed by Bharat Biotech, the American company's partner in India, in collaboration with the Indian Council of Medical Research-National Institute of Virology.
Ocugen CEO Shankar Musunuri and Yahoo Finance's Julie Hyman discuss a range of topics around the company's work on a COVID-19 vaccine as well as vaccine distribution and hesitancy.
Shares of biotech company Ocugen (NASDAQ: OCGN) jumped nearly 13% today as the latest COVID figures show a significant rise in cases, hospitalizations, and deaths -- especially among the unvaccinated. Over the last two weeks, COVID cases are up 140%, while hospitalizations and deaths are up by one-third. Ocugen has partnered with Bharat Biotech, the company responsible for Covaxin, the first COVID vaccine developed in India to receive emergency authorization.